StockNews.AI
ARGX
StockNews.AI
2 days

argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025

1. Extraordinary General Meeting scheduled for November 18, 2025. 2. Shareholders invited to vote on revised remuneration policy. 3. Meeting documents available on argenx's website. 4. Argénx focuses on severe autoimmune diseases and innovative therapies. 5. Company promotes electronic proxy voting for attendance.

4m saved
Insight
Article

FAQ

Why Neutral?

The meeting's agenda mainly covers internal policy changes, historically leading to stable share prices.

How important is it?

While the remuneration policy may affect investor confidence, it's not impactful for significant price movements.

Why Short Term?

Conclusions of the shareholder meeting will have immediate but limited effect on market perception.

Related Companies

VRTXABBVBMY
October 03, 2025 16:01 ET  | Source: argenx SE October 3, 2025 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of shareholders will be held at 14:00 CET on Tuesday, November 18, 2025 at the offices of Freshfields LLP (Netherlands), Strawinskylaan 10, 1077 XZ Amsterdam, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the Extraordinary General Meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting and regarding the e-voting system) is available on the argenx website www.argenx.com and on www.abnamro.com/evoting. Agendaargenx has proposed the adoption of a revised remuneration policy during the meeting. The agenda for the meeting as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available for inspection at the argenx offices. A free copy thereof may also be obtained by e-mailing legal@argenx.com. argenx would like to encourage shareholders to use the voting by (electronic) proxy option as referred to in the convocation. About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube. For further information, please contact:   Media: Ben PetokBPetok@argenx.com Investors: Alexandra Roy  aroy@argenx.com 

Related News